Zydus Cadila has received final approvals from the US health regulator, to market four generic products in America.

The approvals received are for Olanzapine tablets in strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg. This is used to treat Schizophernia and bipolar disorder. Glipizide extended-release tablets are approved in the strengths of 2.5 mg, 5 mg and 10 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Further, Voriconazole for injection has also received approval from USFDA, for use in various fungal infections and Fluocinonide topical solution topical solution 0.05 per cent, is used to treat a variety of skin conditions and reduces the swelling, itching, and redness that can occur in these conditions.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week